search
Back to results

The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots

Primary Purpose

Blood Coagulation Disorders

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Levonorgestrel-containing IUD (Mirena®)
Copper-containing IUD (Paraguard®)
Sponsored by
University of Vermont
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Blood Coagulation Disorders focused on measuring Women's health

Eligibility Criteria

18 Years - 52 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women who desire long-term, reversible contraception

Exclusion Criteria:

  • Women with coagulopathies
  • History of thrombotic events
  • Pregnancy
  • Active pelvic infection
  • Known hypersensitivity to progestin
  • Undiagnosed vaginal bleeding
  • Wilson's disease
  • Sensitivity to copper
  • Uterine anatomy that precludes insertion of an IUD
  • Women with multiple sexual partners and history within the last 5 years of alcoholism or drug abuse.
  • Additionally, women must be greater than 3 months postpartum and have had two months without oral contraceptive pills or 6 months without Depo Provera prior to enrollment.

Sites / Locations

  • University of VermontRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Levonorgestrel-containing intrauterine device insertion

Copper containing intrauterine device

Outcomes

Primary Outcome Measures

The primary outcome of this study will be change in coagulation parameters, with sample size calculations powered to detect a 35% change in D-dimer within groups and a 50% difference between groups.

Secondary Outcome Measures

Patient satisfaction with IUD device
Difference in bleeding patterns between groups

Full Information

First Posted
December 20, 2007
Last Updated
January 15, 2010
Sponsor
University of Vermont
search

1. Study Identification

Unique Protocol Identification Number
NCT00584610
Brief Title
The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots
Official Title
The Effect of a Levonorgestrel-releasing Intrauterine Device Versus a Copper Containing Intrauterine Device on Coagulation Parameters
Study Type
Interventional

2. Study Status

Record Verification Date
January 2010
Overall Recruitment Status
Unknown status
Study Start Date
December 2007 (undefined)
Primary Completion Date
July 2012 (Anticipated)
Study Completion Date
July 2012 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
University of Vermont

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized controlled trial to assess the effect of a levonorgesterel-releasing intrauterine device (LNG IUD, Mirena®) versus a copper IUD (Paraguard®) on coagulation parameters known to be associated with risk of thrombosis (blood clots). Both the LNG IUD and the copper IUD are FDA approved devices for contraception. Women enrolled in this study will be randomized to receive either the LNG IUD or the copper IUD. They will complete a one month bleeding diary prior to insertion of the IUD and again for one month while the IUD is in place. They will undergo phlebotomy (blood draw) at baseline (prior to insertion of the IUD), two and four months. Stored samples will be used to measure D-dimer, C-reactive protein (CRP), antithrombin (AT), factor VIIIc, activated partial thromboplastin time (aPTT) and activated partial thromboplastin time plus activated protein C (aPTT + APC). Both groups will undergo a GYN exam with screening for bacterial vaginosis and gonorrhea/chlamydia cultures prior to insertion of the IUD. A brief survey to assess the women's experience with the IUD, including symptomatology and satisfaction with the device, will be conducted at the four months after insertion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Coagulation Disorders
Keywords
Women's health

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Levonorgestrel-containing intrauterine device insertion
Arm Title
2
Arm Type
Active Comparator
Arm Description
Copper containing intrauterine device
Intervention Type
Device
Intervention Name(s)
Levonorgestrel-containing IUD (Mirena®)
Other Intervention Name(s)
Mirena
Intervention Description
Levonorgestrel-containing intrauterine device insertion
Intervention Type
Device
Intervention Name(s)
Copper-containing IUD (Paraguard®)
Other Intervention Name(s)
Paraguard
Intervention Description
Copper-containing intrauterine device insertion
Primary Outcome Measure Information:
Title
The primary outcome of this study will be change in coagulation parameters, with sample size calculations powered to detect a 35% change in D-dimer within groups and a 50% difference between groups.
Time Frame
4 years
Secondary Outcome Measure Information:
Title
Patient satisfaction with IUD device
Time Frame
4 years
Title
Difference in bleeding patterns between groups
Time Frame
4 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
52 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women who desire long-term, reversible contraception Exclusion Criteria: Women with coagulopathies History of thrombotic events Pregnancy Active pelvic infection Known hypersensitivity to progestin Undiagnosed vaginal bleeding Wilson's disease Sensitivity to copper Uterine anatomy that precludes insertion of an IUD Women with multiple sexual partners and history within the last 5 years of alcoholism or drug abuse. Additionally, women must be greater than 3 months postpartum and have had two months without oral contraceptive pills or 6 months without Depo Provera prior to enrollment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Penny Fairhurst, RN
Phone
802-847-0985
Email
penny.fairhurst@vtmednet.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristen P Wright, MD
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Julia V. Johnson, MD
Organizational Affiliation
University of Massachusetts, Worcester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Vermont
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05405
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots

We'll reach out to this number within 24 hrs